Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID -Dexamethasone versus Rituximab in PGNMID

Clicks: 1
ID: 318261
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #89 of 96 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare renal disorder for which prospective controlled treatment evidence is limited. Clone-directed therapies targeting plasma cells or B cells are increasingly used, but comparative prospective data are lacking. Methods This single-center, open-label, pilot RCT aimed to evaluate the feasibility and preliminary efficacy of plasma cell-targeted therapy (bortezomib-cyclophosphamide-dexamethasone, BCD) versus B-cell-targeted therapy (rituximab, RTX). Twenty eligible patients were randomized (1:1) to receive either 6 cycles of BCD or 4 weekly doses of rituximab at375 mg/m². In patients with B-cell reconstitution > 5/μL, a 500 mg rituximab booster dose was administered at 6 months according to the prespecified protocol. The primary efficacy endpoint was overall renal response at 12 months. Changes in proteinuria, serum albumin and estimated glomerular filtration rate were also assessed at 6 and 12 months as secondary outcomes. Safety outcomes included infections and hematologic toxicity. Results Baseline characteristics were generally comparable between groups. The median age was 57 years, and mean proteinuria 4.1 ± 3.1 g/d. In the primary intention-to-treat analysis (n = 20), the primary outcome of overall renal response at 12 months was observed in 60% (6/10) of patients in the BCD group and 70% (7/10) in the RTX group (P = 1.0). Treatment failure occurred in 2 patients in the BCD group and none in the RTX group. At 6 months, complete response occurred in five patients in the BCD group and three patients in the RTX group. Both groups showed reductions in proteinuria and improvements in serum albumin over 12 months. A transient decline in estimated glomerular filtration rate was observed in the BCD group at 6 months and recovered by 12 months. Safety profiles were manageable, with one serious adverse event, pneumonia, in the BCD group. Conclusion Both BCD and rituximab were associated with renal responses in this exploratory pilot trial of PGNMID. Given the small sample size, open-label design, and differences in treatment exposure structure, these findings are hypothesis-generating. Larger multicenter studies with longer follow-up are needed to define optimal therapy for PGNMID. Trial registration: chictr.org.cn Identifier: ChiCTR2500102928
Reference Key
openalex_W7165627737 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors X Zhang, Xiaojuan Yu, Zi Wang, Ai-bo Qin, Jinwei Wang, D R Guo, S X Wang, Y H Dong, M H Zhao, Fude Zhou
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag146
URL
https://doi.org/10.1093/ndt/gfag146
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.